VTGN news

Vistagen Therapeutics, Inc. adopted an Executive Severance Plan effective October 7, 2026, to provide key employees with severance payments and other benefits upon resignation or termination without cause, amending the previous Change in Control Executive Severance Plan. This establishes the terms f…

Vistagen Therapeutics provided a corporate presentation outlining a 'nose-to-brain...' strategy, which serves as a marketing tool often associated with assessing a company's development prospects and pipeline management.

Preliminary OLE data shows fasedienol nasal spray was well-tolerated and clinically improved social anxiety symptoms over four months, contributing to its potential for everyday use.

Vistagen Therapeutics, Inc. executed an indemnification agreement with Director Douglas J. Williamson, bolstering protections against executive liability.

Vistagen Therapeutics notified investors that its intranasal social anxiety drug failed to meet primary and secondary endpoints in the PALISADE-4 trial. Despite a post-hoc sign of efficacy in severely ill patients, the company is pivoting to a new FDA discussion regarding a potential registrational …

Vistagen completed the randomized portion of its PALISADE-4 Phase 3 trial evaluating fasedienol for acute social anxiety disorder treatment, with results expected this month. The company also advanced a Phase 2 repeat dose study and received FDA approval to proceed with refisolone development for me…

Vistagen announced its fasedienol nasal spray program for social anxiety disorder has met international safety database exposure standards with over 1,500 subjects enrolled. The milestone supports the company's path toward potential NDA submission, with Phase 3 PALISADE-4 topline results expected in…

Vistagen Therapeutics executed an indemnification agreement effective May 18, 2026 with Dr. Angel S. Angelov, an officer of the company, to protect him against personal liability and advance legal expenses. The agreement includes standard change-of-control provisions and coverage under the company's…